Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PR domain zinc finger protein 12 (PRDM12)
- Target
- PRDM12
- Molecular classification
- Transcription factor, Epigenetic regulator, Histone modification (regulator of histone methylation)
01
Overview
PR domain zinc finger protein 12 (PRDM12) is a transcription factor and epigenetic regulator characterized by a PR domain (related to the SET methyltransferase domain) and multiple zinc finger DNA-binding motifs[1][2][5]. PRDM12 is essential in the specification and maintenance of nociceptor (pain-sensing neuron) development during embryogenesis and has a major role in regulating chromatin structure by modulating histone H3-K9 dimethylation, often through recruitment of histone methyltransferases such as G9a/EHMT2[1][3][4]. Mutations in PRDM12 cause congenital insensitivity to pain by preventing the development of peripheral pain-sensing neurons[1][3][5]. PRDM12 may also act as a tumor suppressor, with alterations implicated in hematological malignancies (notably chronic myeloid leukemia) and solid tumors[1]. There are currently no direct drugs targeting PRDM12, but its essential function in pain and cancer pathways has led it to be considered an attractive potential therapeutic target[3].
- Other names
- PRDM12PR domain-containing protein 12PR domain zinc finger protein 12HSAN8PFM9PR domain containing 12
02
Mechanism of action
Not directly drugged; functions by recruiting histone methyltransferases (such as G9a/EHMT2) to modulate chromatin and transcription[3].
03
Biological functions
Sensory neuronal specificationRegulation of pain perceptionRegulation of histone H3-K9 dimethylation (chromatin modification)Transcriptional repression and gene expression regulationNociceptor development
04
Disease associations
Congenital insensitivity to pain (CIP)Hereditary sensory and autonomic neuropathies (HSAN)Cancer (tumor suppressor, especially in chronic myeloid leukemia and solid tumors)
05
Safety considerations
Loss or inhibition may cause congenital insensitivity to pain, increasing injury risk[1][3][5]Disruption could potentially impact the development or survival of sensory neurons[3]Mutations may contribute to cancer progression or loss of tumor suppressor function[1]
06
Biomarkers
Mutations in PRDM12 (for diagnosis of congenital insensitivity to pain or hereditary sensory and autonomic neuropathies)[1][3][5]
Beyond the preview
Go deeper on PR domain zinc finger protein 12 (PRDM12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR domain zinc finger protein 12 (PRDM12).